US Stock MarketDetailed Quotes

CGEN Compugen

Watchlist

2.2200
+0.0300+1.37%

Close Feb 14 16:00 ET

2.1600
-0.0600-2.70%

Post 20:01 ET

198.77MMarket Cap74.00P/E (TTM)

Compugen Stock Forum

Teddy123

Jan 30 23:37

TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse

$AstraZeneca (AZN.US)$ $Compugen (CGEN.US)$
Major Breakthrough: AstraZeneca's New Weapon Against Early-Stage Lung Cancer Enters Final Testing

Jaguar8

Jan 8 09:36

NEWS TODAY

$Compugen (CGEN.US)$
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
Wednesday, 8th January at 7:00 am
• New approach to harness cytokine biology to treat cancer patients advances to the clinic
• First patient dosed with potential first-in-class anti-IL-18 binding protein antibody, COM503, licensed to Gilead Sciences, Inc.
• Phase 1 dose escalation and dose expansion trial...

Jaguar8

Dec 15, 2024 20:58

🔶December 2024 Upcoming Catalysts. Save it. In alphabetical order

$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...

Jaguar8

Nov 27, 2024 06:03

NEWS

$Compugen (CGEN.US)$
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Compugen (NASDAQ: CGEN) has been granted a new U.S. patent (No. 12152084) covering the triple combination use of its COM902 anti-TIGIT antibody with anti-PD-1 and anti-PVRIG antibodies for cancer treatment.
The patent strengthens Compugen's IP portfolio and protects the use of COM902, a reduc...

Tsukasa0_0

May 30, 2024 22:01

About to Receive Milestone Payment

$Compugen (CGEN.US)$ 🤩
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

Moomoo AI

Mar 8, 2024 05:18

The market anticipates a decline in future revenue, possibly explaining the suppressed P/S. This weak revenue outlook could continue to pressure shares, making it hard to maintain current prices. Shareholders accept the low P/S, expecting future revenue may not bring pleasant surprises.

Compugen Ltd. (NASDAQ:CGEN) Held Back By Insufficient Growth Even After Shares Climb 26%

Moomoo AI

Feb 15, 2024 06:06

Michelle Mahler's appointment as Chief Medical Officer is a positive step for Compugen, thanks to her vast clinical development experience. Her leadership in the COM503 Phase 1 study and future role in advancing COM701, COM902, and COM503 are anticipated to significantly boost the company's clinical development strategy.